ELISA / EIA / RIA Kits · ELISA / EIA kit · Cat. EK-070-94CE
Exendin-4 (Heloderma suspectum) – EIA Kit, CE Mark Certified
Supplied as 96 wells per unit. Species: Heloderma Suspectum. Technical values shown are imported catalog fields and should be confirmed against current documentation. Laboratory research use only.
Specifications
| Catalog number | EK-070-94CE |
|---|---|
| Product type | ELISA / EIA / RIA Kits · ELISA / EIA kit |
| Peptide family | Exendins (Exendin-3, Exendin-4) |
| Species | Heloderma Suspectum |
| Unit size | 96 wells |
| Sensitivity | 0.08 ng/ml |
| Specificity | Peptide % Exendin-4 (Heloderma Suspectum) 100 Exendin-3 (9-39)-NH2 100 Exendin-4 (3-39) 100 Lixisenatide 100 Glucagon (Human, Rat, Mouse, Porcine, Bovine) 0 GLP-1 (7-36)-NH2 (Human, Rat, Mouse) 0 GLP-1 (7-37) (Human, Rat, Mouse) 0 GLP-2 (Human) 0 Oxyntomodulin (Human, Rat, Mouse) 0 |
| Linear Range | 0.08 - 0.86 ng/ml |
| Inter-Assay CV | <15% |
| Intra-Assay CV | <10% |
| Standard Curve | Contact us for technical specifications on this product. To reduce background noise for this kit, do not add EDTA to your samples.Heparin can be used as an alternative to EDTA for this kit. Links to publications that use this kit: C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. Tang D, Tian H, Wu J, et al. J Pharmacol Sci. 2018;138(1):23-30. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner. Liu J, Yang K, Xiao W, et al. Peptides. 2018;106:83-90. The use of low molecular weight protamine to enhance oral absorption of exenatide. Zhang L, Shi Y, Song Y, et al. Int J Pharm. 2018;547(1-2):265-273. Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility. Lee JG, Ryu JH, Kim SM, et al. Biochem Pharmacol. 2018;151:59-68. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation. Chen C, Zheng H, Xu J, Shi X, Li F, Wang X. Daru. 2017;25(1):20. In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4–Fc fusion protein Lian Lu, Xiaoqing Su, Yantai Wang et al., RSC Adv., 2017,7, 54178-54187 An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. Kim D, Jeon H, Ahn S, Choi WI, Kim S, Jon S. J Control Release. 2017;256:114-120. Pyung-Hwan Kim, Minhyung Lee, Sung Wan Kim, Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. J Control Release. 2012 Aug 20;162(1):9-18. doi: 10.1016/j.jconrel.2012.06.010. Epub 2012 Jun 15. Di pasquale G, Dicembrini I, Raimondi L, et al. Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes. PLoS ONE. 2012;7(7):e40074. Nian Gong et al., Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity Br J Pharmacol. 2011 May; 163(2): 399–412. Wei Gao et al., Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats J Pharmacol Exp Ther. 2011 March; 336(3): 881–890. doi: 10.1124/jpet.110.175752 Su Young Chaea, Cheng-Hao Jin et al., Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs Journal of Controlled Release Volume 142, Issue 2, 3 March 2010, Pages 206–213 Kamei et al. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J Control Release. 2009 Feb 27. [Epub ahead of print] Samson et al. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther. 2008 Nov;16(11):1805-12. |
| Sample Extraction | recommended |
| Intended use | In vitro laboratory research only — not for human or veterinary use, diagnostic or therapeutic purposes |
Frequently asked
What is Exendin-4 (Heloderma suspectum) – EIA Kit, CE Mark Certified?
Exendin-4 (Heloderma suspectum) – EIA Kit, CE Mark Certified is a elisa / eia kit elisa / eia / ria kit listed under catalog number EK-070-94CE in the Exendins (Exendin-3, Exendin-4) family, heloderma suspectum sequence. It is supplied as 96 wells per unit for in vitro laboratory research.
What is the intended use of EK-070-94CE?
This catalog listing is for laboratory research use only. It is not represented as a drug, food, supplement, cosmetic or diagnostic product, and it is not offered for human or veterinary use.
This page reproduces an imported research-catalog record. Verify identity, specifications, documentation and suitability before purchase. The item is offered only for laboratory research and is not represented for human or veterinary use.